Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Price Sensitive Information

29th Apr 2010 12:44

RNS Number : 0495L
Beximco Pharmaceuticals Ltd
29 April 2010
 



BEXIMCO PHARMACEUTICALS LTD.

29th April, 2010

PRICE SENSITIVE INFORMATION

 

Beximco Pharmaceuticals Limited ("BPL" or "Company"; AIM Symbol: BXP) today announces information for Shareholders of the Company that the Board of Directors at their meeting held on 29th April, 2010 has decided the following:

 

1. To recommend the approval of the Financial Statements for the year ended 31 December 2009

:

The results are expected to be announced week commencing Tuesday 4th May 2010

2. Date & Time of 34th AGM of the Company for the year 2009

:

15th June, 2010 at 10.00 a.m.

3 Venue of AGM

 

:

Beximco Industrial Park, Sarabo, Kashimpur, Gazipur, Bangladesh

4. Proposed Dividend for year ended 31 December 2009

:

15% Stock dividend (i.e.15 shares for every 100 shares held)

5. Record date

:

19th May, 2010

6. Net Asset Value as at 31 December 2009

:

Taka 10,885,706,614

7. Net Asset Value per share as at 31 December 2009

:

Taka 72.02

8. Net Profit After Tax for the year ended 31 December 2009

:

Taka 624,740,307

9. Earnings per share (EPS) for the year ended 31 December 2009

:

Taka 4.13

10. Net Operating Cash Flow per share for the year ended 31 December 2009

:

Taka 3.45

 

 

For further enquiries please contact:

 

Beximco Pharma

Nazmul Hassan, MP, Managing Director

Tel: +880 2 861 9151, ext.2080

 

Md. Asad Ullah, FCS, Company Secretary

Tel: 88028611891-5. Ext 1140

 

Libertas Capital

Jakob Kinde / Anthony Rowland

Tel: +44 (0)20 7569 9650

 

Financial Dynamics

Jonathan Birt / Susan Quigley

Tel: +44 (0)20 7269 7169

 

 

Notes to Editors

 

About Beximco Pharmaceuticals Limited

Founded in 1976 and based in Dhaka, Bangladesh, BPL manufactures and sells generic pharmaceutical formulation products, active pharmaceutical ingredients and intravenous fluids. The Company also manufactures and markets its own branded generics for almost all diseases. The Company also undertakes contract manufacturing for multinational pharmaceutical companies. The Company operates from a 20 acre site in Dhaka and currently employs over 2,400 staff.

 

The Company's products are sold to retail outlets, medical institutions and other pharmaceutical manufacturers in Bangladesh, in regional markets such as Sri Lanka, Nepal, Bhutan, Vietnam, Cambodia and Myanmar and in other markets overseas, principally in East Africa, Pacific Island and Central American countries and South East Asia, including Singapore and Hong Kong.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCFKLFLBZFXBBK

Related Shares:

Beximco Pharma
FTSE 100 Latest
Value8,474.74
Change-133.74